Hidden seizures in early Alzheimer's? new study uses 48-Hour brain monitor
NCT ID NCT04002583
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses a portable 48-hour EEG monitor to check for hidden seizures in people with early-onset Alzheimer's disease (ages 40-64). Researchers want to learn how common seizures and epilepsy are in this group. The study involves 20 participants and is purely observational, meaning it does not test any new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If this study finds that hidden seizures are common in early-onset Alzheimer's, it could point toward better detection and possibly new treatment approaches for these patients.
- What could go wrong
- This is a small, early-stage observational study with only 20 participants. It is not testing a treatment, so it may not lead to any direct benefit for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2020
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria for EOAD patients will be recruited from the LEADS trial with the following: * 40 to 64 years of age * Meets NIA-AA criteria for mild cognitive impairment (MCI) due to AD or probable AD dementia. * Have a global CDR score of ≤ 1.0 * Have capacity to provide informed consent (ICF) or has a legal authorized representative or guardian who provides IC. * Amyloid positive status (PET scan with evidence of elevated amyloid) * Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, and caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. If the participant does not have a study partner who spends 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI. * Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan * Fluent in English. Exclusion Criteria: * Meets core clinical criteria for non-AD dementia. * Two or more first degree relatives with a history of EOAD suggestive of autosomal dominant transmission, unless known pathogenic mutations in APP, PSEN1, PSEN2 have been excluded. * Known mutation in an ADAD gene (APP, PSEN1, PSEN2) or other autosomal dominant genes associated with other neurodegenerative disorders. * MRI scans with evidence of infection or focal lesions, cortical strokes, multiple lacunes (single lacune is allowable unless it meets criteria for strategic lacune affecting cognition) * Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol (at the discretion of the Site PI) * Medical history of a brain disorder other than the disorder causing dementia except for headache. * Deemed ineligible by the Site PI for any other reason.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Early-onset Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two drugs together stop Alzheimer's plaques from coming back?
- Could Low-Dose radiation slow Alzheimer's? new trial aims to find out
- Major study aims to unlock mysteries of Early-Onset Alzheimer's
- DNA hunt for early Alzheimer's clues
- Simple blood test could spot Alzheimer's early
- New drug targets Alzheimer's proteins in Early-Onset patients